Description
Roxyzin 25 mg Tablet, manufactured by Incepta Pharmaceuticals Ltd., contains Hydroxyzine Hydrochloride as its active ingredient. Hydroxyzine is a sedating antihistamine of the piperazine class, functioning primarily as a histamine H₁ receptor antagonist. It is utilized for the symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states where anxiety is manifested. Additionally, Roxyzin is effective in managing pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses, as well as histamine-mediated pruritus. The tablet also serves as a sedative when used as premedication and following general anesthesia. Hydroxyzine is rapidly absorbed from the gastrointestinal tract, with clinical effects typically noted within 15 to 30 minutes after oral administration. It exhibits antimuscarinic properties and significant sedative effects, along with skeletal muscle relaxation, bronchodilation, antiemetic, and analgesic properties. The effectiveness of Roxyzin as an antianxiety agent for long-term use (over 4 months) has not been assessed by systematic clinical studies, and its use should be periodically reassessed by a healthcare provider.
.jpg)
 400MG.jpg)
.webp)
.jpeg)
.jpeg)
.jpg)
.jpg)
.jpeg)
.webp)
.jpg)
.jpg)
 100 IU 3 ML.webp)
.jpeg)
.jpg)
.jpg)
.png)
.webp)
.jpg)
Change Language